Inclusion Criteria:

- Histologically confirmed melanoma

- Unresectable stage IV disease

- Evidence of metastatic disease

- Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by
conventional techniques OR ≥ 10 mm by spiral CT scan

- No radiologically confirmed invasion of adjacent organs (e.g., duodenum or stomach)

- No tumor invasion of major blood vessels

- No history of primary brain tumor or other CNS disease

- No brain metastases by MRI or CT scan

- Performance status - ECOG 0-2

- More than 4 months

- Absolute granulocyte count ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- Hemoglobin ≥ 9 g/dL (transfusion allowed)

- No active bleeding

- Bilirubin ≤ 1.5 mg/dL

- AST ≤ 3 times upper limit of normal (ULN)

- Alkaline phosphatase ≤ 3 times ULN

- INR ≤ 1.5 times ULN

- PTT normal

- No known esophageal varices

- Creatinine ≤ 1.5 times ULN

- Urine protein creatinine ratio ≤ 0.5

- Urine protein < 1 g/24-hr urine collection

- No New York Heart Association class II-IV congestive heart failure

- No serious cardiac arrhythmia requiring medication

- No myocardial infarction within the past 6 months

- No unstable angina within the past 6 months

- No clinically significant peripheral vascular disease

- No uncontrolled hypertension (i.e., blood pressure ≥ 150/90 mmHg despite
antihypertensive therapy)

- No clinically significant stroke within the past 6 months

- No deep vein thrombosis within the past year

- No other vascular abnormality

- No pulmonary embolus within the past year

- No history of abdominal fistula

- No gastrointestinal perforation

- No intra-abdominal abscess within the past 4 weeks

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for 6 months after
completion of study therapy

- No other pathological condition that would confer a high risk of bleeding

- No active infection requiring parenteral antibiotics

- No serious nonhealing wound (including wounds healing by secondary intention), ulcer,
or bone fracture

- No peripheral neuropathy ≥ grade 2

- No history of allergic reaction attributed to compounds of similar chemical or
biological composition to the study drugs

- No uncontrolled seizures

- No other uncontrolled illness

- No significant traumatic injury within the past 4 weeks

- No prior antivascular endothelial growth factors (VEGF), including any of the
following:

- Bevacizumab

- VEGF Trap

- Anti-VEGF receptor monoclonal antibody

- Small molecular tyrosine kinase inhibitors of VEGF receptors

- No more than 1 prior systemic chemotherapy regimen

- No prior carboplatin or paclitaxel

- No other concurrent chemotherapy

- More than 4 weeks since prior radiotherapy

- No prior radiotherapy to > 25% of bone marrow

- No concurrent radiotherapy

- At least 4 weeks since prior major surgical procedure or open biopsy

- At least 1 week since prior fine-needle aspiration or core biopsy

- No concurrent major surgery

- More than 4 weeks since prior systemic therapy

- No concurrent full-dose oral or parenteral anticoagulation

- No concurrent antiplatelet therapy except low-dose aspirin (i.e., 81 mg of oral
aspirin daily) allowed

- No other concurrent experimental drugs